Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

Cellular & Molecular Immunology volume 8, pages 157–163 (2011)Cite this article

Abstract

Many monoclonal antibodies (mAbs) have been extensively used in the clinic, such as rituximab to treat lymphoma. However, resistance and non-responsiveness to mAb treatment have been challenging for this line of therapy. Complement is one of the main mediators of antibody-based cancer therapy via the complement-dependent cytolysis (CDC) effect. CD59 plays a critical role in resistance to mAbs through the CDC effect. In this paper, we attempted to investigate whether the novel CD59 inhibitor, recombinant ILYd4, was effective in enhancing the rituximab-mediated CDC effect on rituximab-sensitive RL-7 lymphoma cells and rituximab-induced resistant RR51.2 cells. Meanwhile, the CDC effects, which were mediated by rituximab and anti-CD24 mAb, on the refractory multiple myeloma (MM) cell line ARH-77 and the solid tumor osteosarcoma cell line Saos-2, were respectively investigated. We found that rILYd4 rendered the refractory cells sensitive to the mAb-mediated CDC effect and that rILYd4 exhibited a synergistic effect with the mAb that resulted in tumor cells lysis. This effect on tumor cell lysis was apparent on both hematological tumors and solid tumors. Therefore, rILYd4 may serve as an adjuvant for mAb mediated-tumor immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Glennie MJ, French RR, Cragg MS, Taylor RP . Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823–3837.

    Article  CAS  PubMed  Google Scholar 

  2. Villamor N, Montserrat E, Colomer D . Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003; 30: 424–433.

    Article  CAS  PubMed  Google Scholar 

  3. Zhou X, Hu W, Qin X . The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008; 13: 954–966.

    Article  CAS  PubMed  Google Scholar 

  4. Morgan BP, Harris CL . Complement Regulatory Proteins. London: Academic Press, 1999.

    Google Scholar 

  5. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 2010; 184: 359–368.

    Article  CAS  PubMed  Google Scholar 

  6. Yu Q, Yu R, Qin X . The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol 2010; in press.

  7. Juhl H, Melmig F, Baltzer K, Kalthoff H, Hennebruns D, Kremer B . Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 1997; 64: 222–230.

    Article  CAS  PubMed  Google Scholar 

  8. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S . Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14–25.

    Article  CAS  PubMed  Google Scholar 

  9. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R et al. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997; 71: 1049–1055.

    Article  CAS  PubMed  Google Scholar 

  10. Coral S, Fonsatti E, Sigalotti L, de Nardo C, Visintin A, Nardi G et al. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. J Cell Physiol 2000; 185: 317–323.

    Article  CAS  PubMed  Google Scholar 

  11. Fonsatti E, Altomonte M, Coral S, de Nardo C, Lamaj E, Sigalotti L et al. Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. Clin Ter 2000; 151: 187–193.

    CAS  PubMed  Google Scholar 

  12. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908.

    CAS  PubMed  Google Scholar 

  13. Harjunpaa A, Junnikkala S, Meri S . Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634–641.

    Article  CAS  PubMed  Google Scholar 

  14. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389.

    Article  CAS  PubMed  Google Scholar 

  15. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S . Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625–631.

    Article  CAS  PubMed  Google Scholar 

  16. Bjorge L, Stoiber H, Dierich MP, Meri S . Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scand J Immunol 2006; 63: 355–364.

    Article  CAS  PubMed  Google Scholar 

  17. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F . Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175–2183.

    Article  CAS  PubMed  Google Scholar 

  18. Macor P, Piovan E, Zorzet S, Tripodo C, Marzari R, Amadori A et al. Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab. Mol Immunol 2007; 44: 212.

    Article  Google Scholar 

  19. Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C . In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 2009; 15: 851–857.

    Article  CAS  PubMed  Google Scholar 

  20. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486–5495.

    Article  CAS  PubMed  Google Scholar 

  21. Castillo J, Milani C, Mendez-Allwood D . Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Exp Opin Invest Drugs 2009; 18: 491–500.

    Article  CAS  Google Scholar 

  22. Maddocks KJ, Lin TS . Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2009; 2: 29.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M . Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109–123.

    Article  CAS  PubMed  Google Scholar 

  24. Bonavida B . Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629–3636.

    Article  CAS  PubMed  Google Scholar 

  25. Zhao XJ, Zhao J, Zhou Q, Sims PJ . Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59. J Biol Chem 1998; 273: 10665–10671.

    Article  CAS  PubMed  Google Scholar 

  26. Bodian DL, Davis SJ, Morgan BP, Rushmere NK . Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 1997; 185: 507–516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Husler T, Lockert DH, Sims PJ . Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59. Biochemistry 1995; 35: 3263–3269.

    Article  Google Scholar 

  28. Huang Y, Fedarovich A, Tomlinson S, Davies C . Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallogr D Biol Crystallogr 2007; 63: 714–721.

    Article  CAS  PubMed  Google Scholar 

  29. Huang Y, Qiao F, Abagyan R, Hazard S, Tomlinson S . Defining the CD59-C9 binding interaction. J Biol Chem 2006; 281: 27398–27404.

    Article  CAS  PubMed  Google Scholar 

  30. Giddings KS, Zhao J, Sims PJ, Tweten RK . Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. Nat Struct Mol Biol 2004; 11: 1173–1178.

    Article  CAS  PubMed  Google Scholar 

  31. Hu W, Ferris SP, Tweten RK, Wu G, Radaeva S, Gao B et al. Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 2008; 14: 98–103.

    Article  CAS  PubMed  Google Scholar 

  32. LaChapelle S, Tweten RK, Hotze EM . Intermedilysin-receptor interactions during assembly of the pore complex: assembly intermediates increase host cell susceptibility to complement-mediated lysis. J Biol Chem 2009; 284: 12719–12726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tweten RK . Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 2005; 73: 6199–6209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hughes TR, Ross KS, Cowan GJ, Sivasankar B, Harris CL, Mitchell TJ et al. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Mol Immunol 2009; 46: 1561–1567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR . Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008; 141: 135–148.

    Article  CAS  PubMed  Google Scholar 

  36. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24: 263–271.

    Article  CAS  PubMed  Google Scholar 

  37. Kolb EA, Gorlick R . Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 2009; 11: 307–313.

    Article  CAS  PubMed  Google Scholar 

  38. Loeb DM . Is there a role for immunotherapy in osteosarcoma? Cancer Treat Res 2010; 152: 447–457.

    Article  Google Scholar 

  39. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556–10563.

    Article  CAS  PubMed  Google Scholar 

  40. Donev RM, Gray LC, Sivasankar B, Hughes TR, van den Berg CW, Morgan BP . Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res 2008; 68: 5979–5987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhao WP, Zhu B, Duan YZ, Chen ZT . Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 2009; 21: 1405–1411.

    CAS  PubMed  Google Scholar 

  42. Shi XX, Zhang B, Zang JL, Wang GY, Gao MH . CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer. Cell Mol Immunol 2009; 6: 61–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Treon SP, Raje N, Anderson KC . Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27: 598–613.

    CAS  PubMed  Google Scholar 

  44. Treon SP, Anderson KC . The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27: 79–85.

    CAS  PubMed  Google Scholar 

  45. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P . Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154–1161.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the US NIH through grant RO1 AI061174 (XBQ) and grant R21 CA141324 (XBQ), the Harvard Technology Development Accelerator Fund (XBQ), and the Fund of the China Scholarship Council No. 2008638052 (TY). We are grateful to Ms Annie Qin, a Harvard University undergraduate student, for helpful editorial assistance.

Author information

Authors and Affiliations

  1. Department of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

    Tao You & Jingnan Shen

  2. Laboratory for Translational Research, Harvard Medical School, Cambridge, MA, USA

    Tao You, Weiguo Hu, Xiaowen Ge & Xuebin Qin

  3. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

    Tao You, Weiguo Hu & Xuebin Qin

Authors
  1. Tao You
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weiguo Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaowen Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingnan Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xuebin Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuebin Qin.

Additional information

Note: Supplementary information is available on the Cellular & Molecular Immunology website.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

You, T., Hu, W., Ge, X. et al. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells. Cell Mol Immunol 8, 157–163 (2011). https://doi.org/10.1038/cmi.2010.35

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2010.35

Keywords

This article is cited by

Search

Advanced search

Quick links